Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12–49.

• PubMed
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12–49.)| false
• Search Google Scholar
• Export Citation

D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281–286.

• PubMed
D’Amico AV, Whittington R, Malkowicz SB, Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281–286.)| false
• Search Google Scholar
• Export Citation

D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.

• PubMed
D’Amico AV, Whittington R, Malkowicz SB, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.)| false
• Search Google Scholar
• Export Citation

Tom MC, Reddy CA, Smile TD, et al. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy 2020;19:43–50.

• PubMed
Tom MC, Reddy CA, Smile TD, Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy 2020;19:43–50.)| false
• Search Google Scholar
• Export Citation

Berlin A, Moraes FY, Sanmamed N, et al. International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy. J Urol 2019;201:284–291.

• PubMed
Berlin A, Moraes FY, Sanmamed N, International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy. J Urol 2019;201:284–291.)| false
• Search Google Scholar
• Export Citation

Pompe RS, Karakiewicz PI, Tian Z, et al. Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN guideline. J Urol 2017;198:354–361.

• PubMed
Pompe RS, Karakiewicz PI, Tian Z, Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN guideline. J Urol 2017;198:354–361.)| false
• Search Google Scholar
• Export Citation

Xu H, Zhu Y, Dai B, et al. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl 2018;20:551–554.

• PubMed
Xu H, Zhu Y, Dai B, National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl 2018;20:551–554.)| false
• Search Google Scholar
• Export Citation

Dess RT, Suresh K, Zelefsky MJ, et al. Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging collaboration for cancer of the prostate. JAMA Oncol 2020;6:1912–1920.

• PubMed
Dess RT, Suresh K, Zelefsky MJ, Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging collaboration for cancer of the prostate. JAMA Oncol 2020;6:1912–1920.)| false
• Search Google Scholar
• Export Citation

Zelic R, Garmo H, Zugna D, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol 2020;77:180–188.

• PubMed
Zelic R, Garmo H, Zugna D, Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol 2020;77:180–188.)| false
• Search Google Scholar
• Export Citation

Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med 2021;145:461–493.

• PubMed
Epstein JI, Amin MB, Fine SW, The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med 2021;145:461–493.)| false
• Search Google Scholar
• Export Citation

Ho MD, Ross AE, Eggener SE. Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance. J Urol 2023;210:38–45.

• PubMed
Ho MD, Ross AE, Eggener SE. Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance. J Urol 2023;210:38–45.)| false
• Search Google Scholar
• Export Citation

Roberts MJ, Maurer T, Perera M, et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol 2023;20:23–47.

• PubMed
Roberts MJ, Maurer T, Perera M, Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol 2023;20:23–47.)| false
• Search Google Scholar
• Export Citation

Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment of localised prostate cancer. Eur Urol 2015;68:186–193.

• PubMed
Castro E, Goh C, Leongamornlert D, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment of localised prostate cancer. Eur Urol 2015;68:186–193.)| false
• Search Google Scholar
• Export Citation

Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748–1757.

• PubMed
Castro E, Goh C, Olmos D, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748–1757.)| false
• Search Google Scholar
• Export Citation

Carter HB, Helfand B, Mamawala M, et al. Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol 2019;75:743–749.

• PubMed
Carter HB, Helfand B, Mamawala M, Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol 2019;75:743–749.)| false
• Search Google Scholar
• Export Citation

Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Williston Park) 1997;11:180–193.

• PubMed
Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Williston Park) 1997;11:180–193.)| false
• Search Google Scholar
• Export Citation

Logothetis C, Millikan R, Baker LH, et al. Update: NCCN Practice Guidelines for Treatment of Prostate Cancer. Oncology (Williston Park) 1999;13:118–132.

• PubMed
Logothetis C, Millikan R, Baker LH, Update: NCCN Practice Guidelines for Treatment of Prostate Cancer. Oncology (Williston Park) 1999;13:118–132.)| false
• Search Google Scholar
• Export Citation

Bahnson RR, Hanks GE, Huben RP, et al. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) 2000;14:111–119.

• PubMed
Bahnson RR, Hanks GE, Huben RP, NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) 2000;14:111–119.)| false
• Search Google Scholar
• Export Citation

Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–374.

• PubMed
Epstein JI, Walsh PC, Carmichael M, Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–374.)| false
• Search Google Scholar
• Export Citation

Shee K, Cowan JE, Balakrishnan A, et al. Limited relevance of the very low risk prostate cancer classification in the modern era: results from a large institutional active surveillance cohort. Eur Urol 2023;84:9–12.

• PubMed
Shee K, Cowan JE, Balakrishnan A, Limited relevance of the very low risk prostate cancer classification in the modern era: results from a large institutional active surveillance cohort. Eur Urol 2023;84:9–12.)| false
• Search Google Scholar
• Export Citation

Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol 2022;208:10–18.

• PubMed
Eastham JA, Auffenberg GB, Barocas DA, Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol 2022;208:10–18.)| false
• Search Google Scholar
• Export Citation

Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446–1452.

• PubMed
Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446–1452.)| false
• Search Google Scholar
• Export Citation

Vince RA Jr, Jiang R, Qi J, et al. Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis 2022;25:677–683.

• PubMed
Vince RA Jr, Jiang R, Qi J, Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis 2022;25:677–683.)| false
• Search Google Scholar
• Export Citation

Spratt DE, Lio VY, Michalski J, et al. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase III trial. Int J Radiat Oncol Biol Phys 2023;117:370–377.

• PubMed
Spratt DE, Lio VY, Michalski J, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase III trial. Int J Radiat Oncol Biol Phys 2023;117:370–377.)| false
• Search Google Scholar
• Export Citation

Nguyen PL, Huang HR, Spratt DE, et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 phase 3 randomized trials. Int J Radiat Oncol Biol Phys 2023;116:521–529.

• PubMed
Nguyen PL, Huang HR, Spratt DE, Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 phase 3 randomized trials. Int J Radiat Oncol Biol Phys 2023;116:521–529.)| false
• Search Google Scholar
• Export Citation

Attard G, Parry M, Grist E, et al. Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone phase 3 trial. Res Sq. Preprint posted online February 8, 2023. doi:10.21203/rs.3.rs-2488586/v1

• PubMed
Attard G, Parry M, Grist E, Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone phase 3 trial. Res Sq. Preprint posted online February 8, 2023. doi:10.21203/rs.3.rs-2488586/v1)| false
• Search Google Scholar
• Export Citation

Feng FY, Huang HC, Spratt DE, et al. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial. JAMA Oncol 2021;7:544–552.

• PubMed
Feng FY, Huang HC, Spratt DE, Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial. JAMA Oncol 2021;7:544–552.)| false
• Search Google Scholar
• Export Citation

Dal Pra A, Ghadjar P, Hayoz S, et al. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy—an ancillary study of the SAKK 09/10 randomized clinical trial. Ann Oncol 2022;33:950–958.

• PubMed
Dal Pra A, Ghadjar P, Hayoz S, Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy—an ancillary study of the SAKK 09/10 randomized clinical trial. Ann Oncol 2022;33:950–958.)| false
• Search Google Scholar
• Export Citation

Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428–1434.

• PubMed
Cooperberg MR, Simko JP, Cowan JE, Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428–1434.)| false
• Search Google Scholar
• Export Citation

Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245–255.

• PubMed
Cuzick J, Swanson GP, Fisher G, Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245–255.)| false
• Search Google Scholar
• Export Citation

Canter DJ, Reid J, Latsis M, et al. Comparison of the prognostic utility of the cell cycle progression score for predicting clinical outcomes in African American and non-African American men with localized prostate cancer. Eur Urol 2019;75:515–522.

• PubMed
Canter DJ, Reid J, Latsis M, Comparison of the prognostic utility of the cell cycle progression score for predicting clinical outcomes in African American and non-African American men with localized prostate cancer. Eur Urol 2019;75:515–522.)| false
• Search Google Scholar
• Export Citation

Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550–560.

• PubMed
Klein EA, Cooperberg MR, Magi-Galluzzi C, A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550–560.)| false
• Search Google Scholar
• Export Citation

Esteva A, Feng J, van der Wal D, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 2022;5:71.

• PubMed
Esteva A, Feng J, van der Wal D, Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 2022;5:71.)| false
• Search Google Scholar
• Export Citation

Spratt DE, Tang S, Sun Y, et al. Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid 2023;2:EVIDoa2300023.

• PubMed
Spratt DE, Tang S, Sun Y, Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid 2023;2:EVIDoa2300023.)| false
• Search Google Scholar
• Export Citation

Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388:1547–1558.

• PubMed
Hamdy FC, Donovan JL, Lane JA, Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388:1547–1558.)| false
• Search Google Scholar
• Export Citation

Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–1424.

• PubMed
Hamdy FC, Donovan JL, Lane JA, 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–1424.)| false
• Search Google Scholar
• Export Citation

Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425–1437.

• PubMed
Donovan JL, Hamdy FC, Lane JA, Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425–1437.)| false
• Search Google Scholar
• Export Citation

Neal DE, Metcalfe C, Donovan JL, et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol 2020;77:320–330.

• PubMed
Neal DE, Metcalfe C, Donovan JL, Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol 2020;77:320–330.)| false
• Search Google Scholar
• Export Citation

Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2023;389:1453–1465.

• PubMed
Freedland SJ, de Almeida Luz M, De Giorgi U, Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2023;389:1453–1465.)| false
• Search Google Scholar
• Export Citation